Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 679804, 8 pages
http://dx.doi.org/10.1155/2013/679804
Research Article

Trichostatin A Promotes the Generation and Suppressive Functions of Regulatory T Cells

1Departamento de Ciencias Biológicas, Universidad Andrés Bello, República 275, Santiago, Chile
2Fundación Ciencia & Vida, Avenida Zañartu 1482, Ñuñoa, Santiago, Chile
3Laboratorio de Inmunología, Departamento de Biología, Facultad de Ciencias, Las Palmeras 3425, Ñuñoa, Universidad de Chile, Santiago, Chile
4Universidad San Sebastián, Avenida Lota 2465, Providencia, Santiago, Chile

Received 30 January 2013; Revised 9 April 2013; Accepted 9 April 2013

Academic Editor: Nicolaus Kroger

Copyright © 2013 Cristian Doñas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Khattri, T. Cox, S. A. Yasayko, and F. Ramsdell, “An essential role for Scurfin in CD4+CD25+ T regulatory cells,” Nature Immunology, vol. 4, no. 4, pp. 337–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3 programs the development and function of CD4+CD25+ regulatory T cells,” Nature Immunology, vol. 4, no. 4, pp. 330–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. J. H. Buckner and S. F. Ziegler, “Functional analysis of FOXP3,” Annals of the New York Academy of Sciences, vol. 1143, pp. 151–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Dejaco, C. Duftner, B. Grubeck-Loebenstein, and M. Schirmer, “Imbalance of regulatory T cells in human autoimmune diseases,” Immunology, vol. 117, no. 3, pp. 289–300, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. B. M. Javierre, H. Hernando, and E. Ballestar, “Environmental triggers and epigenetic deregulation in autoimmune disease,” Discovery Medicine, vol. 12, no. 67, pp. 535–545, 2011. View at Google Scholar
  6. A. C. Jenke and M. Zilbauer, “Epigenetics in inflammatory bowel disease,” Current Opinion in Gastroenterology, vol. 28, no. 6, pp. 577–584, 2012. View at Publisher · View at Google Scholar
  7. T. Kouzarides, “Chromatin modifications and their function,” Cell, vol. 128, no. 4, pp. 693–705, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Liu, A. Mai, and J. Sun, “Lysine acetylation regulates Bruton's tyrosine kinase in B cell activation,” Journal of Immunology, vol. 184, no. 1, pp. 244–254, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. R. W. Johnstone, “Histone-deacetylase inhibitors: novel drugs for the treatment of cancer,” Nature Reviews Drug Discovery, vol. 1, no. 4, pp. 287–299, 2002. View at Google Scholar · View at Scopus
  10. T. A. McKinsey and E. N. Olson, “Cardiac histone acetylation—therapeutic opportunities abound,” Trends in Genetics, vol. 20, no. 4, pp. 206–213, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. M. A. Glozak, N. Sengupta, X. Zhang, and E. Seto, “Acetylation and deacetylation of non-histone proteins,” Gene, vol. 363, no. 1-2, pp. 15–23, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. H. J. Kim and S. C. Bae, “Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs,” The American Journal of Translational Research, vol. 3, no. 2, pp. 166–179, 2011. View at Google Scholar · View at Scopus
  13. R. Tao, E. F. de Zoeten, E. Ozkaynak et al., “Deacetylase inhibition promotes the generation and function of regulatory T cells,” Nature Medicine, vol. 13, no. 11, pp. 1299–1307, 2007. View at Publisher · View at Google Scholar
  14. N. Mishra, C. M. Reilly, D. R. Brown, P. Ruiz, and G. S. Gilkeson, “Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse,” Journal of Clinical Investigation, vol. 111, no. 4, pp. 539–552, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. J. M. A. Moreira, P. Scheipers, and P. Sørensen, “The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses,” BMC Cancer, vol. 3, article 30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Minucci and P. G. Pelicci, “Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer,” Nature Reviews Cancer, vol. 6, no. 1, pp. 38–51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M. D. Säemann, G. A. Böhmig, C. H. Osterreicher et al., “Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production,” The FASEB Journal, vol. 14, no. 15, pp. 2380–2382, 2000. View at Google Scholar · View at Scopus
  18. J. van Loosdregt, Y. Vercoulen, T. Guichelaar et al., “Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization,” Blood, vol. 115, no. 5, pp. 965–974, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Misaki, A. Morinobu, J. Saegusa et al., “Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice,” Arthritis Research and Therapy, vol. 13, no. 3, article R77, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Deaglio, K. M. Dwyer, W. Gao et al., “Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression,” Journal of Experimental Medicine, vol. 204, no. 6, pp. 1257–1265, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. C. T. Huang, C. J. Workman, D. Flies et al., “Role of LAG-3 in regulatory T cells,” Immunity, vol. 21, no. 4, pp. 503–513, 2004. View at Publisher · View at Google Scholar · View at Scopus